Zevra Therapeutics, Inc. ZVRA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue, net by Product | ||||||
| MIPLYFFA | $94.9M+8.6% | $87.4M+37.6% | $63.53M+45.5% | $43.65M+76.9% | $24.68M+144% | |
| OLPRUVA | $1M+25.0% | $800K+33.3% | $600K+20.0% | $500K+150% | $200K0.0% | |
| Segment long-lived assets by Geography | ||||||
| Europe | $1.5M-6.3% | $1.6M-5.9% | $1.7M— | —— | —— | |
| UNITED STATES | $8.2M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zevra Therapeutics, Inc. break its business down?
- Zevra Therapeutics, Inc. (ZVRA) reports revenue, net by product across 2 parts — MIPLYFFA and OLPRUVA. Each is extracted from the segment footnotes and tracked over time.
- Where does Zevra Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zevra Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
